Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $26 from $30 and keeps a Buy rating on the shares. While ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Hutchmed (HCM) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals for $608M in cash to GP Health Service Capital and Shanghai ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million: Hong Kong, Shanghai Friday, January 3, 2025, 13:00 H ...

(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering ...